Neoadjuvant Immunotherapy for Early-stage High-risk, ER+/HER2– Breast Cancer: Physician Practices, Therapy Choice, and Barriers Among U.S. Oncologists

<u>Authors</u>: Puja Aggarwal, PhD, BDS, MPH¹; Bryce Van Doren, MPH, MPA, MA; Yolaine Jeune-Smith, PhD¹; Luke Jennings-Zhang, PharmD¹; Brooke Leon BA¹; Robert N. Bone, PhD¹; Saeed Sadeghi, MD²; Neil M. Iyengar, MD³; Bruce Feinberg, DO^{1*}

*Presenting author

¹Cardinal Health, Dublin, Ohio, USA; ²University of California, Los Angeles, CA, USA;

³Memorial Sloan Kettering Cancer Center, New York, NY, USA

Poster code: HSD49

Background

- Despite improved prognosis among patients with early-stage estrogen receptor positive (ER+) human epidermal growth factor receptor 2 negative (HER2–) breast cancer, those with higher-risk disease (e.g., larger and higher-grade tumors, lymph node-positive disease) continue to experience a substantial risk of recurrence.¹
- Neoadjuvant treatment in this setting can limit tumor growth and enhance surgical outcomes.
- Current therapy options include anthracycline and taxane regimens with ongoing research exploring the use of immunotherapy with pembrolizumab or nivolumab.²
- The phase III KEYNOTE-756 trial revealed that addition of neoadjuvant pembrolizumab (versus placebo) to chemotherapy prior to surgery, followed by adjuvant pembrolizumab (versus placebo) and endocrine therapy, resulted in a significant increased pathological complete response among

Results, continued

Figure 3: Top Factors in Neoadjuvant Treatment Selection

Question: Assuming that all treatment options are safe, affordable, and covered by insurance, which of the following factors would most influence your treatment selection for patients with early-stage, high-risk, ER+/HER2– breast cancer in the neoadjuvant setting? Please select up to 2.

Nodal involvement			54%	n=98
Stage of disease			45%	
Comorbidities		31%		
Menopausal status	12%			
Surgical feasibility	12%			
Risk status	11%			
Safety profile	0%			

patients with early-stage, high-risk, ER+, HER2– breast cancer.³⁻⁵

Objective

• This survey-based study aimed to examine US oncologists' utilization and perceptions of neoadjuvant treatment options in early-stage, high-risk, ER+/HER2- breast cancer.

Methods


- US-based oncologists/hematologists attended two live meetings in February and March 2024 to discuss clinical updates from scientific meetings, including the 2023 San Antonio Breast Cancer Symposium.
- A survey to assess clinical practices regarding neoadjuvant therapy for early-stage high-risk, ER+/HER2– breast cancer and perceptions of KEYNOTE-756 was administered to the physicians.
- Participant demographics and practice details were collected via an online premeeting survey.
- Aggregate responses were summarized using descriptive statistics.

Results

 Among respondents (N=98), 76% were community-based with an average of 20.6 years of clinical experience.

Before reviewing KEYNOTE-756

- Over one-quarter of respondents reported use of neoadjuvant therapy in ≥40% of patients with early-stage, high-risk, ER+/HER2– breast cancer in the past 6 months.
- Nearly two-thirds of respondents reported a preference for neoadjuvant chemotherapy for early-stage high-risk, ER+/HER2– breast cancer.
- Respondents reported nodal involvement (54%) and stage of disease (45%) as top influential factors in neoadjuvant treatment selection.



After reviewing KEYNOTE-756 data

Figure 4: Potential Use of Neoadjuvant Pembrolizumab + Chemotherapy

Question: Based on the KEYNOTE-756 data and assuming FDA approval and/or guideline recommendation, which of the following best describes your anticipated utilization of neoadjuvant pembrolizumab + chemotherapy for patients with early-stage, high-risk, ER+/HER2– breast cancer?





Figure 5: Physician Perceptions of Subgroups which benefit most with addition of Pembrolizumab to Neoadjuvant Chemotherapy

Question: After reviewing the KEYNOTE-756 data for patients with early-stage, high-risk, ER+/HER2– breast cancer, which of the following subgroups would most benefit from the addition of pembrolizumab to chemotherapy in the neoadjuvant setting? Please select up to 2.



After reviewing KEYNOTE-756

- Nearly 96% of respondents anticipated they would incorporate neoadjuvant pembrolizumab plus chemotherapy for early-stage, high-risk, ER+/HER2– breast cancer patient subgroups including positive lymph nodes, those with programmed death-ligand 1 (PD-L1) combined positive score (CPS) ≥1, and PD-L1 CPS ≥1 and ER-positivity <10%.
- Respondents reported that top barriers to prescribing neoadjuvant immunotherapy included limited long-term survival data (54%), cumbersome payer approval process (29%), and toxicity concerns (27%).

Table 1: Physician demographics and characteristics

	Count (%) (N=98)
Region of practice (n, %)*	
Midwest	21 (21)
Northeast	20 (20)
South	23 (24)
West	34 (35)
Practice setting (n, %)	
Community	74 (76)
Academic	22 (22)
Other	2 (2)
Primary medical specialty (n, %)	
Medical oncology	45 (46)
Hematology oncology	51 (52)
Other	2 (2)

Before reviewing KEYNOTE-756 data

Figure 1: Preference for Neoadjuvant Therapy


Question: Within the past 6 months, what proportion of your patients with early-stage, high-risk, ER+/HER2– breast cancer received neoadjuvant therapy?

۲ 100%		n=98
80%-		11-20
60% -		
00%		
400/	720/2	260/2

positive lymph nod involvement	e $CPS \ge 1$	$CPS \ge 1$ and ER -positivity <10%	stage II	convincing	
Involvement		LR-positivity < 10%			

Figure 6: Perceived Barriers for Use of Neoadjuvant Immunotherapy

Question: After reviewing the KEYNOTE-756 data and assuming FDA approval and/or guideline recommendation, which of the following do you perceive as the greatest barriers to using neoadjuvant immunotherapy for patients with early-stage, high-risk, ER+/HER2– breast cancer? Please select up to 2.



Conclusions

- Overall, oncologists were receptive to adding pembrolizumab to neoadjuvant chemotherapy for high risk, ER+/HER2- breast cancer after reviewing data from the KEYNOTE-756 trial.
- Other ongoing investigations into survival data from KEYNOTE-756 holds promise for informing neoadjuvant treatment decisions and optimizing therapy selection in ER+/HER2– breast cancer.
- If approved by the FDA, the KEYNOTE-756 regimen may provide a new standard of care for this
 patient population.
- It remains to be seen how these data will impact clinical practice, and these data can be enhanced through future real-world evidence studies designed to identify the optimal neoadjuvant therapy for





Figure 2: Preferred Neoadjuvant Regimen

Question: What is your preferred neoadjuvant treatment regimen for patients with early-stage, high-risk (i.e., T2N1), ER+/HER2– breast cancer?



patients with ER+/HER2- breast cancer.

References

- 1. Fountzila Elena, Ignatiadis Michail (2020) Neoadjuvant immunotherapy in breast cancer: a paradigm shift? ecancer 14 1147
- 2. Lucas MW, Kelly CM. Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights. *Cancer Manag Res.* 2022;14:2493-2506. Published 2022 Aug 17. doi:10.2147/CMAR.S341466
- 3. Cardoso F, McArthur HL, Schmid P, et al. LBA21 KEYNOTE-756: phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. *Ann Oncol.* 2023;34(suppl 2):S1260-S1261. doi:10.1016/j.annonc.2023.10.011
- 4. https://www.cancernetwork.com/view/keynote-756-trials-shows-increased-response-in-er-her2--breast-cancer
- 5. Nanda R, Liu MC, Yau C, et al. Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial. *JAMA Oncol*. 2020;6(5):676-684. doi:10.1001/jamaoncol.2019.6650

Acknowledgements

The authors thank Ryan Laughlin for the poster development, and Samantha Buford for project management assistance, and all Cardinal Health team members for help developing this study.

Presented at: ISPOR Europe 2024 | November 17-20, 2024 | Barcelona, Spain